Repligen (NASDAQ:RGEN) Reaches New 1-Year High at $101.36

Repligen Co. (NASDAQ:RGEN)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $101.36 and last traded at $101.15, with a volume of 32434 shares changing hands. The stock had previously closed at $100.71.

A number of research analysts recently issued reports on the company. BidaskClub upgraded Repligen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 8th. HC Wainwright restated a “buy” rating and set a $110.00 price target on shares of Repligen in a report on Monday, January 13th. Leerink Swann assumed coverage on Repligen in a report on Tuesday, October 15th. They set an “outperform” rating and a $100.00 price target on the stock. First Analysis upgraded Repligen from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $107.00 to $110.00 in a report on Friday, November 1st. Finally, ValuEngine downgraded Repligen from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $105.63.

The company has a 50-day simple moving average of $93.25 and a two-hundred day simple moving average of $87.14. The company has a debt-to-equity ratio of 0.25, a quick ratio of 14.70 and a current ratio of 16.03. The firm has a market capitalization of $5.20 billion, a P/E ratio of 204.43, a PEG ratio of 4.60 and a beta of 1.12.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, October 31st. The biotechnology company reported $0.26 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.07. The business had revenue of $69.45 million for the quarter, compared to analysts’ expectations of $66.10 million. Repligen had a return on equity of 6.50% and a net margin of 9.28%. The business’s revenue was up 40.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.20 EPS. As a group, research analysts forecast that Repligen Co. will post 1.03 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. Lenox Wealth Advisors LLC bought a new stake in Repligen during the 4th quarter valued at approximately $31,000. Nisa Investment Advisors LLC boosted its position in Repligen by 62.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 470 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 180 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in Repligen by 94.2% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 639 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 310 shares in the last quarter. Allred Capital Management LLC bought a new stake in Repligen during the 4th quarter valued at approximately $69,000. Finally, Centaurus Financial Inc. bought a new stake in Repligen during the 2nd quarter valued at approximately $129,000. 85.46% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile (NASDAQ:RGEN)

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Recommended Story: Float

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.